Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
Identifieur interne : 001557 ( Main/Exploration ); précédent : 001556; suivant : 001558Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
Auteurs : Cheryl H. Waters [États-Unis] ; Kapil D. Sethi [États-Unis] ; Robert A. Hauser [États-Unis] ; Eric Molho [États-Unis] ; John M. Bertoni [États-Unis]Source :
- Movement Disorders [ 0885-3185 ] ; 2004-04.
English descriptors
- KwdEn :
Abstract
Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first‐pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double‐blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia‐free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of “Asleep” time throughout the study. No apparent differences were detected in the occurrence of drug‐related adverse events between the Zydis selegiline group and placebo‐treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20036
Affiliations:
- États-Unis
- Floride, Géorgie (États-Unis), Nebraska, État de New York
- New York, Tampa
- Université Columbia, Université de Floride du Sud
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study</title><author><name sortKey="Waters, Cheryl H" sort="Waters, Cheryl H" uniqKey="Waters C" first="Cheryl H." last="Waters">Cheryl H. Waters</name></author><author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D." last="Sethi">Kapil D. Sethi</name></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name></author><author><name sortKey="Molho, Eric" sort="Molho, Eric" uniqKey="Molho E" first="Eric" last="Molho">Eric Molho</name></author><author><name sortKey="Bertoni, John M" sort="Bertoni, John M" uniqKey="Bertoni J" first="John M." last="Bertoni">John M. Bertoni</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:34804F14A74A295F7D9F066389878EC0EC2F1742</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20036</idno><idno type="url">https://api.istex.fr/document/34804F14A74A295F7D9F066389878EC0EC2F1742/fulltext/pdf</idno><idno type="wicri:Area/Main/Corpus">002937</idno><idno type="wicri:Area/Main/Curation">002586</idno><idno type="wicri:Area/Main/Exploration">001557</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study</title><author><name sortKey="Waters, Cheryl H" sort="Waters, Cheryl H" uniqKey="Waters C" first="Cheryl H." last="Waters">Cheryl H. Waters</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Columbia University, New York, New York</wicri:regionArea><placeName><region type="state">État de New York</region><settlement type="city">New York</settlement></placeName><orgName type="university">Université Columbia</orgName></affiliation></author><author><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D." last="Sethi">Kapil D. Sethi</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Medical College of Georgia, Augusta, Georgia</wicri:regionArea><placeName><region type="state">Géorgie (États-Unis)</region></placeName></affiliation></author><author><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><affiliation wicri:level="4"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Movement Disorder Center, University of South Florida, Tampa, Florida</wicri:regionArea><placeName><region type="state">Floride</region><settlement type="city">Tampa</settlement></placeName><orgName type="university">Université de Floride du Sud</orgName></affiliation></author><author><name sortKey="Molho, Eric" sort="Molho, Eric" uniqKey="Molho E" first="Eric" last="Molho">Eric Molho</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Parkinson's Disease and Movement Disorder Center of Albany Medical Center, Albany, New York</wicri:regionArea><placeName><region type="state">État de New York</region></placeName></affiliation></author><author><name sortKey="Bertoni, John M" sort="Bertoni, John M" uniqKey="Bertoni J" first="John M." last="Bertoni">John M. Bertoni</name><affiliation wicri:level="2"><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Neurology, Creighton University Medical Center, Omaha, Nebraska</wicri:regionArea><placeName><region type="state">Nebraska</region></placeName></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="sub">Official Journal of the Movement Disorder Society</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-04">2004-04</date><biblScope unit="volume">19</biblScope><biblScope unit="issue">4</biblScope><biblScope unit="page" from="426">426</biblScope><biblScope unit="page" to="432">432</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">34804F14A74A295F7D9F066389878EC0EC2F1742</idno><idno type="DOI">10.1002/mds.20036</idno><idno type="ArticleID">MDS20036</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>MAO‐B inhibition</term><term>Parkinson's disease</term><term>Zydis selegiline</term><term>efficacy</term><term>motor fluctuations</term><term>safety</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Zydis selegiline dissolves on contact with saliva and undergoes pregastric absorption. This minimizes first‐pass metabolism and provides high plasma concentrations of selegiline. In this study, the efficacy and safety of Zydis selegiline was assessed in Parkinson's disease (PD) patients who were experiencing motor fluctuations with levodopa. Patients were randomly assigned to either drug or placebo in a 2:1 ratio in this double‐blind, multicenter trial. Significant reductions in daily off time occurred at 4 to 6 weeks with the 1.25 mg dose (9.9%, P = 0.003) and 10 to 12 weeks with the 2.5 mg dose (13.2%, P < 0.001). The total number of off hours was reduced by 2.2 hours at Week 12 from baseline (compared with 0.6 hours in the placebo group). The average number of dyskinesia‐free on hours for the Zydis selegiline patients increased by 1.8 hours at Week 12. There was no change in mean percentage of “Asleep” time throughout the study. No apparent differences were detected in the occurrence of drug‐related adverse events between the Zydis selegiline group and placebo‐treated groups. Adverse events were consistent with known effects of levodopa therapy. Zydis selegiline safely reduces daily off time when used as adjunctive therapy with levodopa in patients with PD. © 2004 Movement Disorder Society</div></front></TEI><affiliations><list><country><li>États-Unis</li></country><region><li>Floride</li><li>Géorgie (États-Unis)</li><li>Nebraska</li><li>État de New York</li></region><settlement><li>New York</li><li>Tampa</li></settlement><orgName><li>Université Columbia</li><li>Université de Floride du Sud</li></orgName></list><tree><country name="États-Unis"><region name="État de New York"><name sortKey="Waters, Cheryl H" sort="Waters, Cheryl H" uniqKey="Waters C" first="Cheryl H." last="Waters">Cheryl H. Waters</name></region><name sortKey="Bertoni, John M" sort="Bertoni, John M" uniqKey="Bertoni J" first="John M." last="Bertoni">John M. Bertoni</name><name sortKey="Hauser, Robert A" sort="Hauser, Robert A" uniqKey="Hauser R" first="Robert A." last="Hauser">Robert A. Hauser</name><name sortKey="Molho, Eric" sort="Molho, Eric" uniqKey="Molho E" first="Eric" last="Molho">Eric Molho</name><name sortKey="Sethi, Kapil D" sort="Sethi, Kapil D" uniqKey="Sethi K" first="Kapil D." last="Sethi">Kapil D. Sethi</name></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/ParkinsonV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001557 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 001557 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Sante
|area= ParkinsonV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:34804F14A74A295F7D9F066389878EC0EC2F1742
|texte= Zydis selegiline reduces off time in Parkinson's disease patients with motor fluctuations: A 3‐month, randomized, placebo‐controlled study
}}
| This area was generated with Dilib version V0.6.23. |  |